Crompton R Michael 4

4 · MICRUS ENDOVASCULAR CORP · Filed Sep 28, 2010

Form 4

Period: 2010-09-27

VP Regulatory,Clinical&Quality

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−10,625$150,981→ 0 total
Exercise: $9.19Exp: 2019-05-26→ Common Stock (10,625 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.89/sh−4,167$24,544→ 0 total
Exercise: $17.51Exp: 2017-11-12→ Common Stock (4,167 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−15,549$186,277→ 0 total
Exercise: $11.42Exp: 2018-05-14→ Common Stock (15,549 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$10.77/sh−28,332$305,136→ 0 total
Exercise: $12.63Exp: 2016-10-02→ Common Stock (28,332 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−4,451$53,323→ 0 total
Exercise: $11.42Exp: 2018-05-14→ Common Stock (4,451 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−19,375$275,319→ 0 total
Exercise: $9.19Exp: 2019-05-26→ Common Stock (19,375 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.89/sh−15,833$93,256→ 0 total
Exercise: $17.51Exp: 2017-11-12→ Common Stock (15,833 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$10.77/sh−31,668$341,064→ 0 total
Exercise: $12.63Exp: 2016-10-02→ Common Stock (31,668 underlying)

Footnotes (1)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of $23.40 over the per share exercise price of such stock option, without interest.

Documents

1 file